STAR-TREC

Population: Patients with biopsy proven adenocarcinoma of the rectum, staged as TX/T1/T2/T3, NX/N0, MX/M0 via MRI or ERUS, ECOG PS 0-1, choosing an organ preserving treatment and randomised to receive either long-course chemoradiotherapy (Radiotherapy 25x2Gy plus concurrent capecitabine 825 mg/m2 bd on radiotherapy days over 5 weeks) or short-course radiotherapy (5x5Gy over 5 days). Patients showing tumour progression, poor or no response to (chemo) radiation at 11-13 weeks will undergo Total Mesorectal Excision (TME) surgery. Patients showing incomplete response at 16-20 weeks will undergo Transanal Endoscopic Microsurgery (TEM). Identification of high-risk histopathological features in TEM specimens will prompt conversion to TME. Samples taken: A) Blood derived ctDNA obtained at randomisation, week 16-20 and 6, 12, 18 and 24 months from the start of (chemo)radiotherapy. B) Formalin-fixed paraffin embedded tissue blocks obtained from the biopsy specimen taken to confirm presence of rectal adenocarcinoma and from any subsequent surgical procedure (TEM and/or TME) required to excise the tumour.

Existing samples:

  • Malignant tumor of rectum (disorder)

Bespoke collection capabilities:

  • Malignant tumor of rectum (disorder)

Contact Information

Email:
STAR-TREC@trials.bham.ac.uk
Telephone:
+44(0)1214143973
Address:

STAR-TREC UK Coordinating Centre
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston, Birmingham
West Midlands
B15 2TT
England

Last Updated: 13/10/2020


Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A